| Name | Diprotin A TFA |
|---|
| Description | Diprotin A (TFA) is an inhibitor of dipeptidyl peptidase IV (DPP-IV). |
|---|---|
| Related Catalog | |
| Target |
DPP-IV[1]. |
| In Vitro | Diprotin A increases the phosphorylation of Src and vascular endothelial-cadherin (VE-cadherin) in human endothelial cells and disrupts endothelial cell-to-cell junctions, which are attenuated by CXCR4 (receptor of SDF-1α)-blocker or Src-inhibitor[1]. |
| In Vivo | In the model of retinopathy of prematurity, Diprotin A increases not only retinal vascularity but also leakage. Additionally, in the murine diabetic retinopathy model, Diprotin A increases the phosphorylation of Src and VE-cadherin and aggravates vascular leakage in the retinas. Collectively, Diprotin A induces vascular leakage by augmenting the SDF-1α/CXCR4/Src/VE-cadherin signaling pathway[1]. |
| References |
| Molecular Formula | C19H32F3N3O6 |
|---|---|
| Molecular Weight | 455.47 |
| Storage condition | 2-8℃ |